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Received March 21, 2014; accepted August 14, 2014AbstractDiabetes mellitus (DM) is a global health care issue resulting from hyperglycemia-mediated life-threatening complications. Although the use
of glucose-lowering agents is routinely practiced, high dependence on medication leads to poor quality of life for DM patients. While it is still
not feasible to precisely determine the critical timing when DM is truly established, perhaps the best way to reduce DM-associated mortality is to
prevent it. To this end, an exploration of prognostic molecules sensitive enough to detect early physiological alteration at the initiating stage
would be required. Recently discovered small noncoding molecules, microRNAs (miRs), in body fluid seem promising to be utilized as a
biomarker to monitor DM initiation and progression, as it is believed that expression of circulating miRs reflects disease pathology. Current DM-
related miRs were often referred to miRs differentially expressed in insulin target organs (liver, muscle, and adipose tissues) or circulating blood
(peripheral blood) in diabetic patients compared to their control counterparts, although these miRs could merely be resultant nucleotides from
DM-induced organ impairment instead of the indicators of onset/progression of DM. In the current review, studies showing circulating miRs
associated with type 2 DM and its complications are summarized, and future scope of using miRs as biomarkers for disease prognosis/diagnosis
is also emphasized.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: biomarkers; complications; diabetes mellitus; diagnosis; microRNAs1. Introduction
Diabetes mellitus (DM), a global public health issue, was
estimated to affect ~450 million people, and the economic cost
is projected at $490 billion/year by 2030.1 The disease results
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Ass(type 1 DM, T1DM) or from ineffective insulin action (type 2
DM, T2DM).2 As for T1DM, in addition to conventional in-
sulin injection, whole pancreas/islet transplantation has been
considered the most promising clinical procedure to restore
normoglycemia. The shortage of cadaveric islets for trans-
plantation, however, has been the main obstacle for this
treatment.3 T2DM is more common, comprising 85e90% of
total DM cases, and has been considered a progressive meta-
bolic disorder characterized by reduced insulin sensitivity and
eventual pancreatic b-cell dysfunction.4 Aberrant physiolog-
ical conditions often lead to adverse effects on multiple organs
as well as life-threatening complications, accounting for major
DM-related mortality including cardiovascular disease, kidneyociation. All rights reserved.
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damage (neuropathy). While prescription/use of a number of
insulin sensitizers (e.g., rosiglitazone) to promote insulin
sensitivity of the insulin target organs is often practiced, tight
glycemic control by routine exercise and diet is also a major
way of lessening the risk of DM-associated mortality.5,6
Although clinical procedure for treatment of DM patients
has been fairly well established, to completely cure DM, there
remains a critical need to better understand the underlying
mechanisms of the onset and progression of the disease in order
to develop advanced therapeutic strategies. While various
pathophysiological stages of DM development have been
defined, it is still not feasible to precisely determine the critical
timing when DM is truly established.7 This may be due to the
lack of prognostic molecules sensitive enough to monitor the
dynamic changes of pre-DM status, namely impaired fasting
glucose (IFG)/impaired glucose tolerance (IGT), to insulin
resistance and finally to frank DM condition. In this regard,
perhaps the best way to “cure” DM is to prevent it; specific
clinical biomarkers with the potential to revolutionize diagnosis
and treatment of DM are therefore required. Recent studies
taking advantage of a metabolomic analysis uncovered possible
metabolic molecules to differentiate IFG from overt T2DM.8
However, the analysis is time- and labor-consuming and may
not be objective enough, leaving this new method to be further
evaluated prior to its translation to the bedside.
2. Biogenesis of (circulating) microRNA and its
association with DM
In clinics, an ideal biomarker should be easily accessible by
using a minimally invasive sampling procedure, making
routine blood, urine, or saliva examination an excellent source
of choice. Blood carries a wide array of biomolecules
including nutrients, hormones, and molecules secreted by cells
with specific biological functions.9 Among these molecules,
circulating nucleic acids such as microRNAs (miRs) have
recently been recognized to be present in the circulation sys-
tem, providing useful diagnostic indicators.10 These miRs
were first detected in blood serum/plasma in 200811 and
subsequently shown to also be present in urine, saliva, tears,
and breast milk.12,13 These comprise a group of small, single-
stranded, 22e25-nucleotide-long, noncoding RNA molecules
that normally bind to the 30untranslated region of their target
mRNA, leading to translational inhibition and/or mRNA
degradation.14 It has been reported that distinct miR expres-
sion profiles regulate various physiological and pathological
conditions.15 The miRs are initially transcribed as long pri-
mary miRs sequentially processed to a hairpin-like fragment,
termed precursor miR, in the nucleus by an RNase III enzyme
Drosha and the double-stranded RNA-binding protein
DGCR8. Precursor miRs are then exported to the cytoplasm by
Exportin-5 protein, followed by the cleavage of miR duplexes
by another RNase III enzyme Dicer. The miR duplexes are
then unwound and the guide strand, which has complemen-
tarity to target mRNAs, is loaded into RNA-induced silencing
complex (RISC) containing Argonaute 2, Dicer, and TRBPproteins for gene silencing. If the complementarity of a miR to
target an RNA is perfectly matched, RISC cleaves the target
mRNA. Most miRs exhibited mismatches with their target
mRNAs, resulting in RISC-induced translational repression of
target genes by hybridization of miRs to their 30untranslated
region, leading to repression of the initiation and elongation
steps of translation, thereby decreasing protein expression. In
addition to their role in post-transcriptional repression, miRs
are also implicated in transcriptional gene silencing by tar-
geting the promoter regions.16e18 Over 1000 miRs have been
discovered in the human genome, and it has been estimated
that they could regulate 74e92% of all protein-encoding
mRNAs in a tissue- and/or cell-specific manner.19 Since
miRs can regulate a wide range of biological events, including
cell growth and proliferation, differentiation, organogenesis,
metabolism, stress response, and tissue remodeling, detection
of miR expression can be implicated in physiological/patho-
logical changes and it can even be useful for the prognosis or
diagnosis of the onset/progression of diseases.20e23
Due to various pathogeneses of different DM types, the
differential regulatory roles of miRs leading to disease out-
comes, including b-cell deficiency and insulin resistance, have
recently been defined. For T1DM, the role of miRs in control-
ling b-cell genesis, b-cell death (e.g., miR-21), insulin produc-
tion (e.g., miR-30d, miR-204, and miR-124a), and a/b-cell mass
balance (miR-375) or its susceptibility to immune-mediated b-
cell destruction has been described.24e29 When the possibility
that a different set of miRs could control compensatory b-cell
mass under pre-DM or gestational DM (GDM) condition was
recently examined, the results showed that expression of miRs
in omental adipose tissues (miR-222), placentas (miR-518d), or
isolated rodent islets (miR-338-3p) are differentially expressed
in GDM compared to controls,30e33 suggesting that these miRs
are important for regulating b-cell mass in response to physio-
logical demand. In regard to T2DM, a number of review articles
have provided a broad overview of the possible functions of
different miRs in regulating insulin sensitivity and glucose uti-
lization activity in insulin target tissues, including adipose,
muscle, liver, and pancreatic b cells, from T2DM as well as
obese individuals.34e37 In general, miRs related to insulin
resistance were often identified based on the differential
expression of candidate miRs in insulin target cells of DM and
non-DM individuals. It is interesting that most of insulin
resistance-related miRs are also key regulators of cellular ho-
meostasis. In brief, insulin sensitivity-related miRs in adipo-
cytes (miR-21, miR-29, miR-93, miR-103, miR-143, and miR-
320),38e42 muscle (miR-1, miR-106b, miR-133a, and miR-
223),42e44 and liver (Let-7, miR-130a-3p, miR-143, miR-181a,
and miR-802)45e49 were essential in maintaining physiological
homeostasis and energy balance. Taken together, miRs could be
differentially expressed in various types of DM, suggesting their
potential to be DM indicators.
3. MicroRNAs serve as circulating DM biomarkers
The miRs present in the circulation system represent a
remarkably stable form, making them ideal materials to
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that expression patterns of circulating miRs are reflective of
underlying pathological/physiologic processes.10,50,51 Based
on the fact that RNases are abundant in circulating blood, the
requirement of distinct mechanism(s) to protect miRs from
degradation was proposed. El-Hefnawy and colleagues52 first
showed that plasma RNA is protected from degradation by its
inclusion in protein or lipid vesicles. Depending on their size
and mode of release from cells, these particles are classified as
exosomes (50e100 nm), microvesicles (0.1e1 mm), or
apoptotic bodies (0.5e2 mm).53 Circulating miRs can also be
released in complexes with RNA-binding proteins such as
Argonaute 2 or lipoprotein complexes with high-density li-
poprotein.54,55 Although the precise cellular release mecha-
nisms of miRs remain largely unknown, a recent study
revealed that these circulating miRs may be delivered to
recipient cells, where they can regulate translation of target
genes, suggesting that circulating miRs can serve as extra-
cellular communicators.56,57
The miRs present in the serum or plasma seem promising
for utilization as biomarkers to identify disease initiation and
progression. In agreement with findings of other diseases such
as cancer and cardiovascular disease, it was recently recog-
nized that there are distinct profiles of circulating miRs in
patients with DM and T2DM complications compared to non-
DM patients.58 Studies have shown that specific miR profiles
are correlated to DM pathology, while all candidate miRs are
involved in regulating insulin production machinery, insulin
sensitivity, glucose homeostasis, or lipid metabolism impli-
cated in T2DM pathology.59e61 Regarding the involvement of
miRs to predict patients at risk for DM complications, various
miRs were described as playing a crucial role to regulate
homeostasis of tissues where DM complications occur.20
Interestingly, a recent investigation revealed an ethnicity-
specific DM-related miR profile. Among 14 selected miRs
(miR-15a, miR-20, miR-21, miR-24, miR-29b, miR-126, miR-
144, miR-150, miR-197, miR-223, miR-191, miR-320a, miR-
486-5p, and miR-28-3p) in plasma from 19 Iraqis and 14
Swedes diagnosed with T2DM and 119 control patients, the
expression of miR-24 and miR-29b was significantly different
between the T2DM patients and the control group after
adjustment for age, sex, waist circumference, a family history
of T2DM, and a sedentary lifestyle. A higher expression of
miR-144 was significantly associated with T2DM in Swedes
but not in Iraqis, implying that miR-144 is an ethnicity-
specific DM-associated miR.62 Moreover, by using an un-
usual DM cat as the model, expression of circulating miR-122,
miR-193b, and miR-483 in serum was found to be signifi-
cantly greater in newly diagnosed DM cats than that in healthy
lean cats and cats in diabetic remission, suggesting an
important evolutionary role of circulating miRs in regulating
DM pathophysiology.63
Zampetaki and colleagues64 first reported that miR-20b,
miR-21, miR-24, miR-15a, miR-126, miR-191, miR-197,
miR-223, miR-320, and miR-486 were downregulated, while
miR-28-3p was upregulated in plasma of T2DM patients in
comparison with non-DM individuals. Further follow-up studyshowed that normoglycemic patients who developed DM over
a 10-year follow-up period could be identified using the five
most significant differentially expressed miRs (miR-15a, miR-
126, miR-320, miR-223, and miR-28-3p), indicating that these
miRs could be potential biomarkers for the diagnosis or even
prediction of DM. More recent studies also detected signifi-
cantly increased levels of circulating miR-146a65 and miR-
12666 in newly diagnosed T2DM patients compared with
healthy controls. In addition to plasma miRs, serum miRs have
also been used in different studies to explore DM biomarkers.
It was shown that seven candidate miRs (miR-9, miR-29a,
miR-30d, miR-34a, miR-124a, miR-146a, and miR-375)
were significantly increased in serum from newly diagnosed
T2DM patients compared with T2DM-susceptible individuals
with normal glucose tolerance in a Chinese cohort, implying
their potential as biomarkers for T2DM.67 Interestingly, a
similar pattern of these miRs was observed in pre-DM (IGT/
IFG) and T2DM-susceptible individuals with normal glucose
tolerance, suggesting that during the pathogenesis of T2DM,
DM-related miRs are not significantly changed in serum. A
report of further study aiming to explore potential diagnostic
circulating miRs in genetic-susceptible DM, HNF1A-MODY
(maturity onset diabetes of the young due to a mutation in
HNF1A), recently implied that HNF1A-MODY pathophysi-
ology is associated with the overexpression of miR-103 and
miR-224.68 The miR expression in T2DM using whole-blood
samples was also recently highlighted. Karolina et al69
analyzed eight miRs (miR-144, miR-146a, miR-150, miR-
182, miR-192, miR-29a, miR-30d, and miR-320a) in IGT
and T2DM, and found that all eight tested miRs were differ-
entially expressed. Among them, increased circulating miR-
144 was found to correlate with its decreased potential target
gene insulin receptor substrate 1, a key molecule in insulin
signaling.
Taken together, differential miR expression profiles can
be good indicators for DM prediction or disease progression;
incoherent DM-related miRs from different studies, however,
this would need to be clarified further. Inconsistency in
results from different investigations could possibly be due to
ethnic variance of samples or different inclusion/exclusion
criteria in different trials, thereby leading to difficult
interpretation and comparison between various in-
vestigations. Furthermore, studies using whole-blood sam-
ples that might contain circulating cells that affect miR
signature could also be a concern when comparing results
using plasma or serum.
4. Biological significance of DM-associated circulating
miRs
While different sets of miRs related to DM pathophysi-
ology were identified in various studies, it is essential to
further define the specific roles of these miRs in controlling
insulin activity and maintaining normal physiology of insulin
target organs under DM condition. In addition, miR-mediated
regulations in different biological materials by various
experimental methods should be clarified.
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patientsThe distinct miR profile in peripheral blood mononuclear
cells (PBMCs) from DM patients may correlate with disease
pathology. Recent studies showed that miR-126, miR-146a,
and miR-155 were downregulated in PBMCs in response to
hyperglycemic/diabetic conditions, suggesting that miR-
mediated impaired proangiogenic effect and deregulated
cellular metabolic control could be underlying molecular
mechanisms for T2DM pathogenesis.70,71 A more recent
report showing differential miR expression in PBMCs from
T1DM, T2DM, and GDM revealed that PBMCs could be used
as reporter cells to characterize different DM manifestations.
The study indicated that nine tested miRs, including miR-126,
miR-1307, miR-142-3p, miR-142-5p, miR-144, miR-199a-5p,
miR-27a, miR-29b, and miR-342-3p, were shared among
T1DM, T2DM, and GDM as the miR profiles in T1DM (miR-
1274a, miR-1274b, and let-7f), T2DM (miR-222, miR-30e,
and miR-140-3p), and GDM (miR-181a and miR-1268)
were distinctly expressed, representing molecular signatures
for each type of DM.71 On a molecular basis, the studies
further identified potential links between individual DM miRs
and disease manifestation. For example, miR-126 expression
in DM inhibited endothelial progenitor cell (EPC) prolifera-
tion and migration, and might induce apoptosis, thereby
leading to DM-mediated cardiovascular diseases.72 As for the
modulation of DM-mediated intracellular signals, miR-144
was shown to target insulin receptor substrate 1, a pathway
highly involved in glucose homeostasis and insulin-mediated
cell growth, suggesting its significance in contributing to
pathophysiology in both T1DM and T2DM patients.69
Furthermore, the miR-29 family was also shown to be essen-
tial to maintain cellular physiology, including insulin-
stimulated glucose uptake of b cells, signal transmission of
neuronal cells, and cellular fibrosis in kidneydall of which are
potential features resulting in DM complications.73e754.2. Correlation of miR expression with T2DM-related
vascular dysfunctionAmong the vast array of long-term DM-associated complica-
tions, almost 80% of DM-associated mortality is due to cardio-
vascular diseases, resulting mainly from endothelial dysfunction.
Despite all efforts and advancement made to address this global
burden, the challenge to clinicians remains large.76 Recent studies
suggested that several miRs play important roles in regulating
endothelial function and angiogenesis under condition of DM
cardiovascular complications. For example, it was shown that
exposure to hyperglycemic conditions decreased the expression of
c-kit, the receptor for stem cell factor, and deregulatedmigration of
human umbilical vein endothelial cells through induction of miR-
221.77Additionally, it was also found thatDMcondition decreased
the number and impaired the function of EPCs, the cells important
for endothelial regeneration in response to pathological chal-
lenges.78,79 Another study demonstrated that miR-126 expression
was downregulated in EPCs from DM patients compared to thecontrol group, whereas deregulated miR-126 level impaired EPC-
mediated vascular function by controlling its target Spred-1 and
downstream Ras/ERK/VEGF and PI3K/Akt/eNOS signaling
pathways.72 More recently, it was further reported that elevated
miR-21 could be detected in primary cultured EPCs from DM
patients compared to those from control individuals, and that
increased miR-21 could protect EPCs from apoptosis via the
regulation of downstream target DAXX.80 Taken together, the
detection of deregulated miR profile in circulating peripheral
blood cells or vascular cells may potentially be associated with
T2DM pathological conditions.4.3. Extracellular indicators of DM complicationRegarding involvement of miRs in predicting DM patients
at risk for complications, the number of miRs has been found
to play a key physiological role in tissues where DM com-
plications occur. However, whether these miRs are involved in
DM-associated tissue damage requires further clarification.20
Taking diabetic nephropathy (DN) as an example, recent ef-
forts have been directed toward elucidating potential DN-
associated miRs. DN is the leading cause of kidney failure,
affecting the glomerulus and resulting in progressive kidney
scarring and fibrosis.81,82 A recent study defined the role of
miRs in renal disease and showed the importance of specific
miRs in normal renal development and function, suggesting
that specific renal miRs might be ideal candidates for moni-
toring DN initiation and progression.83 Several potential miRs
have been proposed to serve as DN miRs. For example, miR-
192 was found to be specifically expressed in the kidney, and
its expression is upregulated in streptozotocin-induced DM
and db/db mice.84 In this study, it was also reported that miR-
192 suppressed the translation of SIP1/E-box repressor ZEB2,
a transcriptional repressor that binds to the E-box in the col-
lagen1a2 (col1a2) gene, leading to increased col1a2 expres-
sion in vitro and elevated collagen deposition in vivo,
suggesting a role of miR-192 in the development of the matrix
accumulation observed in DN.85 In addition to DN, miR-192
has also been correlated with disease severity and progres-
sion in patients with immunoglobulin A nephropathy and
hypertensive nephrosclerosis, indicating that miR-192 may
also play a role in renal diseases.20 Other DN-associated miRs
such as miR-21 and miR-29 were also described. Expression
of miR-21 was downregulated in response to early DN.
Ectopic miR-21 expression in vivo resulted in decreased
albuminuria in db/db mice, suggesting its role in maintaining
renal functions in response to high-glucose condition as well
as in preventing renal fibrosis and regulating renal cell
death.20,85 Recent reports also linked miR-29 to renal fibrosis
based on the detection of decreased expression of miR-29 in
fibrotic kidney of obstructive nephropathy. Knockdown of
miR-29c significantly reduced albuminuria and kidney
mesangial matrix accumulation, and prevented high-glucose-
induced cell apoptosis in db/db mice, whereas forced expres-
sion of miR-29c strongly induced podocyte apoptosis.86
Most previous studies aiming to identify DN miRs were
performed using either in vitro cultured renal cells or diabetic
Table 1
DM-associated circulating microRNAs.
Sample type DM miRs Impact (significance, complications) Refs
T2DM; plasma [ miR-20b, miR-21, miR-24, miR-15a, miR-126,
miR-191, miR-197, miR-223, miR-320, and miR-486
Y miR-28-3p
Elucidation of potential underlying molecular
cues for impaired peripheral angiogenic
signaling in patients with pre-DM condition/T2DM
66
T2DM; plasma [ miR-146a, miR-126 Identification of possible predictors for newly
onset T2DM
67,68
T2DM; serum [ miR-9, miR-29a, miR-30d, miR-34a, miR-124a,
miR-146a, and miR-375
69
HNF1a-MODY; serum [ miR-103 and miR-224 Definition of pathological molecular players and
potential predictor for HNF1a-MODY
70
IGF/T2DM; whole blood [ miR-144, miR-150, miR-192, miR-29a, and
miR-320
Y miR-146, miR-182, and miR-30d
Link of circulating microRNAs with intracellular
signaling pathway in pre-DM/T2DM patients
71
T2DM; PBMCs Y miR-126, miR-146a, and miR-155 Significant correlation of microRNA profiles with
clinical parameters (HbA1C, BMI, and glucose level)
72
T1DM/T2DM/GDM; PBMCs miR-1274a, miR-1274b, and let-7f (T1DM specific)
miR-222, miR-30e, and miR-140-3p (T2DM specific)
miR-181a and miR-1268 (GDM specific)
Identification of differential expression of microRNAs
in different DM manifestations
73
T2DM; EPCs Y miR-126
[ miR-21
Explore the role of microRNA in regulating
EPC-mediated endothelial dysfunction in DM patients
80,81
T2DM; urine miR-29a (correlated with albuminuria))
miR-29b (associated with carotid
intima-media thickness)
Definition of biomarkers for monitoring progression
of diabetic nephropathy
90
T2DM; urine [ miRNA-377, miRNA-192, miRNA-216/217,
and miRNA-144
Y miRNA-21 and miRNA-375
93
BMI ¼ body mass index; DM ¼ diabetes mellitus; EPC ¼ endothelial progenitor cell; GDM ¼ gestational diabetes mellitus; HNF ¼ hepatocyte nuclear factor;
IGF ¼ insulin-like growth factor; miR ¼ microRNA; MODY ¼ maturity onset diabetes of the young; PBMC ¼ peripheral blood mononucleated cell;
T1DM ¼ type 1 diabetes mellitus; T2DM ¼ type 2 diabetes mellitus.
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nostic potential for circulating DN-susceptible miRs from
humans was lacking. To this end, in addition to serum or
plasma, urine might also be an alternative sampling material to
determine DN-mediated renal dysfunction, although only
limited studies have been reported. While most urinary nu-
cleotides were wrapped in exosomes, an advanced procedure
to efficiently isolate urinary exosomes was recently sug-
gested.87 By taking advantage of this experimental procedure,
it was recently described that 27 urinary miRs were differen-
tially expressed at different stages of untreated DN in T1DM
patients, as these miRs were mapped to overlapping pathways
of growth factor signaling and renal fibrosis known to be
targeted in DN.88 In addition, it was found that urinary miR-
29a correlated with albuminuria as urinary miR-29b corre-
lated with carotid intima-media thickness in T2DM patients,
revealing their potential to serve as biomarkers for DN and
atherosclerosis in T2DM.89 The regulatory roles of miR-29a
and miR-29b were also demonstrated in proximal tubular
cell HK2 cells in vitro and in mice with established obstructive
nephropathy in vivo, respectively. The results showed that
miR-29a could suppress collagen IV expression and miR-29b
could block progressive renal fibrosis, confirming the anti-
fibrotic properties of miR-29a and miR-29b in DN.90,91
Further analysis of DN-associated regulations of candidate
urinary miRs, including miR-377, miR-192, miR-216/217, and
miR-144 (upregulated in DN patients), as well as miR-21 and
miR-375 (downregulated in DN patients),92 would be required
to better define DN miRs.In conclusion, the potential DM miRs are summarized in
Table 1.66e73,80,81,90,93 Current DM-associated miRs are often
referred to as miRs differentially expressed in insulin target
organs or circulating blood in DM patients compared to their
control counterparts, although these miRs could merely be
resultant nucleotides from DM-induced organ impairment
instead of the indicators of onset/progression of DM. In order
to define DM- or DM-complication-associated miRs more
precisely, more stringent recruitment criteria need to be
considered. For example, differentiating key miRs distinctly
expressed in patients with a DM risk factor (e.g., obesity) and
those with overt T2DM can be very difficult. A recent study
proposed a solution for this issue via comparison of miR
profiles between obese, T2DM, and obese T2DM patients.93
Lastly, further examination using larger population-based
cohort to accurately correlate clinical biochemical variables
will also be required.
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